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Survival rates for children with acute lymphoblastic leukaemia (ALL) have improved 27 
considerably to over 90% in recent years but despite these advances 15-20% of patients 28 
relapse.  Current chemotherapeutic regimens are designed around the properties of bulk 29 
leukaemia cells, which differ from those of the leukaemia initiating cell populations (LIC) 30 
(Cox et al, 2009).  If drugs have no effect on LIC, these cells may proliferate and cause 31 
relapse.  Since several populations in childhood ALL have been shown to have LIC 32 
properties (Cox et al, 2009; Diamanti et al, 2013) developing therapies that are effective 33 
against all leukaemia cells, with minimal toxicity to normal cells, is of utmost importance. 34 
 35 
Efforts to uncover the biological pathways that mediate drug resistance and promote cell 36 
survival have lead to the targeting of heat shock protein (Hsp)90.  Hsp90 is a molecular 37 
chaperone protein involved in maturation and stabilisation of a range of oncogenic client 38 
proteins, such as Bcr-Abl, Akt and IKK, that are known to be mutated and/or overexpressed 39 
in leukaemias (Mjahed et al, 2012).  Targeting Hsp90 could have an impact on several 40 
oncogenic pathways and use of Hsp90 inhibitors is a promising approach for cancer therapy 41 
(Hassane et al, 2008; Hertlein et al, 2010; Lancet et al, 2010; Hong et al, 2013). 42 
 43 
Alvespimycin (17-DMAG) targets the binding site of ATP in Hsp90 and has shown clinical 44 
activity in acute myeloid leukaemia (AML)(Lancet et al, 2010: Mjahed et al, 2012).  Celastrol 45 
has been shown to increase tumour necrosis factor-induced apoptosis (Sethi et al, 2007), 46 
and disrupt the Hsp90/Cdc37 complex (Zhang et al, 2008).  Celastrol significantly impairs 47 
viability and engraftment of AML LIC by inhibiting NF-κB survival signals and inducing 48 
oxidative stress (Hassane et al, 2008).  However, there are no reports on the efficacy of 49 
alvespimycin or celastrol in childhood ALL.  The aim of this study was to examine the effects 50 
of these structurally and functionally distinct Hsp90 inhibitors on primary ALL cells and 51 
evaluate their potential when used in combination. 52 
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 53 
Cells from 3 BCP-ALL, 3 T-ALL and 3 cord blood (CB) cases were incubated with 54 
alvespimycin for 24 hours and celastrol for 48 hours then survival was compared (Fig 1A).  55 
Clinical characteristics of ALL samples are shown in Table S1.  The IC50 for alvespimycin 56 
was reached using 10.2nM in BCP-ALL cases and 43.9nM in T-ALL cases.  Celastrol 57 
reduced the viability of BCP-ALL and T-ALL cells to a similar extent with IC50 of 0.8 and 58 
0.8nM, respectively while the IC50 of CB cells was higher at 2.3nM.  For combination 59 
experiments celastrol was used at 0.1nM and alvespimycin at 1nM and 10nM (Fig 1B).  Both 60 
drug combinations significantly reduced the viability of ALL cells, whilst sparing CB cells.  61 
Using 0.1nM celastrol with 10nM alvespimycin (Hsp90i) reduced BCP-ALL viability to 62 
30.6±11.2% compared to CB (81.4±8.3%, P=0.002), an improvement of 55.8-66.7% over 63 
each drug alone.  Similar in vitro efficacies of celastrol and alvespimycin have been reported 64 
in AML (Hassane et al, 2008) and chronic lymphocytic leukaemia, respectively (Hertlein et 65 
al, 2010).  66 
 67 
To assess the effects of Hsp90i on LIC and haemopoietic stem cells (HSC), cells from 3 68 
additional BCP-ALL cases were stained with anti-CD34 and anti-CD19 and CB cells were 69 
stained with anti-CD34 and anti-CD38 then sorted.  Following treatment with Hsp90i, the 70 
proportions of surviving unsorted and all ALL LIC subpopulations (CD34+/CD19+, 71 
CD34+/CD19-, CD34-/CD19+ and CD34-/CD19-) were significantly reduced (≤5.8±6.9%) 72 
compared to unsorted CB and HSC (P≤0.0003, Fig 1C).  In contrast, unsorted CB and HSC 73 
were largely unaffected (90.8±2.0% and 94.7±26.0% surviving).  Furthermore, Hsp90i had 74 
no detrimental effects on long-term proliferation (Fig S1) or colony formation of CB cells 75 
(data not shown). 76 
 77 
The effects of Hsp90i on the engrafting capacity of LIC was assessed in NOD/LtSz-scid IL-78 
2Rγc null (NSG) mice (Fig 2A).  Treatment with Hsp90i, prior to inoculation, prevented 79 
engraftment of unsorted cells and all LIC subpopulations in 2/3 cases.  In the third case (pt. 80 
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15), engraftment was prevented in NSG inoculated with CD34-/CD7- cells but only reduced 81 
in mice with unsorted (68.7%), CD34+/CD7+ (24.1%) and CD34-/CD7+ (48.4%) cells.  This 82 
sample was from a patient in relapse and therefore may be more resistant.  Hsp90i 83 
treatment did not significantly affect the engrafting capacity of normal HSC (P=0.3, Fig 2B).  84 
These data are more promising than what has been reported in AML, where treatment with 85 
2μM celastrol prior to inoculation into NOD/SCID mice reduced but did not prevent 86 
engraftment in 2/3 cases (Hassane et al, 2008).  87 
 88 
Subsequently, the in vivo efficacy of Hsp90i was assessed in NSG with established disease 89 
(≥4% leukaemia in PB, Fig 2C).  Interestingly, mice engrafted with T-ALL cells from pt.15 90 
initially responded to 5 doses of celastrol (1mg/kg) alone or in combination with 2 doses of 91 
alvespimycin (13mg/kg).  However, after 14 days of treatment, leukaemia levels had 92 
increased and were similar to the placebo-treated group.  Disease burden in NSG engrafted 93 
with BCP-ALL cells from pts 7&8 was not reduced by therapy and most animals did not 94 
complete treatment.  This may be due to high leukaemia burden at commencement of 95 
treatment (up to 70% in some cases) and/or insufficient Hsp90i doses.  Alvespimycin was 96 
used at equivalent doses to that used in patients with advanced AML (Lancet et al, 2010).  It 97 
may be possible to use higher doses of celastrol, as 5mg/kg has been documented in lung 98 
cancer models over a longer time-course than assessed here (Liu et al, 2014).  More 99 
detailed studies will be required to thoroughly assess the in vivo efficacy of these Hsp90 100 
inhibitors in ALL. 101 
 102 
This study represents the first report assessing Hsp90 inhibition both in vitro and in vivo in 103 
childhood ALL and the first description of combining two Hsp90 inhibitors to treat cancer.  As 104 
Hsp90 targeting has a simultaneous impact on signal transduction pathways that are integral 105 
for survival and tumour progression, using Hsp90 inhibitors to treat ALL could prove 106 
beneficial, particularly as toxicity to normal cells was minimal.  While the in vitro data 107 
demonstrated significant elimination of unsorted ALL cells and LIC, in vivo studies need to 108 
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be refined to determine the true potential of these agents alone and in combination with 109 
chemotherapy.   110 
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Figure 1 Response of normal and ALL cells to alvespimycin and celastrol 167 
(A) Dose response curves of normal CB (n=3), BCP ALL (pts. 1, 2, 6) and T-ALL (pts. 15-17) 168 
to alvespimycin (24 hours) and celastrol (48 hours).  Data represent mean ± SD.  (B) Effects 169 
of alvespimycin, celastrol alone and in combination on CB (n=7) and BCP ALL cells (pts. 1-170 
8).  Data represent mean ± SD. ** P≤0.01, *** P≤0.001.  (C) Cell survival of unsorted cells 171 
and LIC subpopulations in BCP ALL cases (pts. 9-11) treated with the 0.1nM celastrol (48 172 
hours) and 10nM alvespimycin (24 hours) in combination.  Unsorted CB (n=7) and sorted 173 
CD34+/CD38- HSC (n=4) were also tested.  Data represent mean ± SD. *** P≤0.001.  174 
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 175 
Figure 2 Ex vivo and in vivo response of ALL and normal cells to Hsp90i treatment 176 
(A) T-ALL cells from pts. 15, 19 & 20 were sorted based on expression/lack of expression of 177 
CD34/CD7 and all subpopulations were treated with the Hsp90i combination 0.1nM celastrol 178 
(48 hours) + 10nM alvespimycin (24 hours).  Both untreated and treated cells (106 unsorted 179 
and 103-106 cells from LIC subpopulations) were subsequently inoculated into NSG mice.  180 
Graph shows percentage of leukaemia cell engraftment in the recipient BM.  (B) 181 
CD34+/CD38- CB HSC (n=3) treated with Hsp90i, as above, were inoculated into NSG mice 182 
and the engrafting capacity compared with untreated cells.  (C) NSG mice engrafted with 106 183 
cells from pts. 7, 8 & 15 were treated with either celastrol at 1mg/kg or 3mg/kg i.p. 5 times 184 
weekly for up to 3 weeks or alvespimycin 13mg/kg i.v. twice weekly for up to 4 weeks or both 185 
drugs in combination.  Graphs show levels of leukaemia cells in PB, each line represents an 186 
individual mouse. 187 
